Picton Mahoney Asset Management’s Blueprint Medicines BPMC Stock Holding History

Picton Mahoney Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-170,000	Closed	-$21.8M	–	1083
2025 Q2	$21.8M	Buy	170,000 +169,783	+78,241%	+$17.6M	0.22%	89
2025 Q1	$20K	Buy	217 +177	+443%	+$17.3K	﹤0.01%	582
2024 Q4	$4K	Buy	40 +15	+60%	+$1.37K	﹤0.01%	571
2024 Q3	$2K	Buy	+25	New	+$2.48K	﹤0.01%	572

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Picton Mahoney Asset Management's BPMC Position: Q3 2025 in Review

Picton Mahoney Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 170,000 shares — an estimated $21.8M sold.

Picton Mahoney Asset Management first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $21.8M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Picton Mahoney Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Picton Mahoney Asset Management sold 170,000 Blueprint Medicines shares in Q3 2025, an estimated $21.8M.
Picton Mahoney Asset Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
Picton Mahoney Asset Management's Blueprint Medicines position peaked at $21.8M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.